Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter:
”First-line treatment for EGFR mutant NSCLC is getting complex with recent approval of FLAURA2.
Would higher risk populations benefit more (e.g. L858R, co-mutations including TP53, RB1, CNS met)?
Thoughtful discussion and great talk by Rachel Sanborn.”
Source: Chul Kim/X
